Cellectar Biosciences (Cellectar Biosciences) Accounts Receivable : $0.00 Mil (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Cellectar Biosciences Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Cellectar Biosciences's accounts receivables for the quarter that ended in Dec. 2023 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Cellectar Biosciences's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $-0.48.

Cellectar Biosciences Accounts Receivable Historical Data

The historical data trend for Cellectar Biosciences's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectar Biosciences Accounts Receivable Chart

Cellectar Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Receivable

Get a 7-Day Free Trial

Cellectar Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accounts Receivable	Get a 7-Day Free Trial															-	-	-	-	-

Cellectar Biosciences Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Cellectar Biosciences Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Cellectar Biosciences's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Cellectar Biosciences's accounts receivable are only considered to be worth 75% of book value:

Cellectar Biosciences's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(9.565	+	0.75 * 0	+	0.5 * 0	-	13.432
-	6.06	-	0)	/	20.7441
=	-0.48

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Cellectar Biosciences Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Cellectar Biosciences's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Cellectar Biosciences (Cellectar Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectar Biosciences Inc (NAS:CLRB) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

NV4:Germany NV4:Germany

Address

100 Campus Drive, Florham Park, NJ, USA, 07932

Website

https://www.cellectar.com

Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. Its lead PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.

Executives

Andrei Shustov	officer: Senior Vice President, Medical	7 PARKLAND DRIVE, MILFORD NJ 08848
Darrell Shane Lea	officer: Chief Commercial Officer	7 PARKLAND DRIVE, MILFORD NJ 08848
Chad J Kolean	officer: Chief Financial Officer	C/O CELLECTAR BIOSCIENCES, INC., 3301 AGRICULTURE DRIVE, MADISON WI 53716
Douglas J Swirsky	director	C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850
Frederick W Driscoll	director
Asher Chanan-khan	director	C/O CELLECTAR BISCIENCES, INC., 100 CAMPUS DRIVE NJ 07932
James V Caruso	director, officer: President and CEO	C/O CELLECTAR BIOSCIENCES, INC., 8383 GREENWAY BLVD STE 600, MIDDLETON WI 53562
Dov Elefant	officer: Chief Financial Officer	EPICEPT CORPORATION, 270 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632
Jarrod Longcor	officer: Chief Business Officer	C/O RIB-X PHARMACEUTICALS, INC., 300 GEORGE STREET, SUITE 301, NEW HAVEN CT 06511
Friend John E. Ii	officer: VP, Chief Medical Officer	26 ORCHARD LANE, COLT NECK NJ 07722
John Neis	director	505 S. ROSA ROAD, SUITE 201, MADISON WI 53719
Stefan Loren	director	3226 AVENIDA DE SUENO, CARLSBAD CA 92009
Stephen A Hill	director	50 AVENUE GENERAL DE GAULLE, BRUXELLES C9 9999999999
Igor D Grachev	officer: Chief Medical Officer	15 REID LANE, MILLSTONE TWP NJ 08535
Bernhardt Charles Thomas Iii	officer: Interim CFO	23 BIRCH ROAD, MALVERN PA 19355